Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Boswellia vs PEA: Boswellia has the stronger overall evidence (7.5 vs 7.5/10); they're alternatives for joint health & mobility — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Boswellia wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
2 of 3 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Boswellia and PEA have evidence — compare verdict strength side-by-side.
300-500mg standardized extract (30-40% AKBA), 2-3x daily (a typical label dose, not the dose used in the cited trials, the one that states its dose gave 100 mg a day of Aflapin, standardized to 20% AKBA)
With meals containing fat
Standardized extract (30-40% AKBA or 65% boswellic acids)
600-1200mg
Two divided doses a day, as in the knee osteoarthritis and burning mouth trials, Or 400 mg three times a day (1,200 mg a day)
Micronised or ultramicronised PEA
4-8 weeks
4-8 weeks
2-4 weeks
2-8 weeks
4-8 weeks
Ongoing
Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-Analysis
Nutrients (2025) · Meta analysis · n=4599
Bayesian rankings indicated Boswellia had the highest probability of being most effective for pain and stiffness, with krill oil and curcumin showing potential for function improvement.
Oral herbal medicines marketed in Brazil for the treatment of osteoarthritis: A systematic review and meta-analysis
Phytotherapy research : PTR (2017) · Meta analysis · n=1741
Z. officinale showed improvement of pain over placebo.
Oral herbal therapies for treating osteoarthritis
The Cochrane database of systematic reviews (2014) · Meta analysis · n=5980
Seventeen studies of confirmatory design (sample and effect sizes pre-specified) were mostly at moderate risk of bias.
Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis
Nutrients (2024) · Meta analysis · n=742
These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month.
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials
Nutrients (2023) · Meta analysis · n=774
PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001).
Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities
Journal of psychopharmacology (Oxford, England) (2025) · Meta analysis · n=2503
Importantly, these treatments were generally well-tolerated, with no significant increase in all-cause dropouts compared to placebo, highlighting their suitability for clinical use in managing agitation in individuals with ASD or ID.
The Cochrane review of oral herbal therapies (PMID 24848732) found high-quality evidence from two trials (85 people) that 100 mg a day of an enriched Boswellia serrata extract for 90 days cut pain by 17 points on a 0 to 100 scale against placebo, with fewer adverse events than placebo in one trial. Effectiveness is that pain reduction. A 250 mg dose of enriched extract showed possible benefit in low-quality evidence from a single small study, so it is plotted flat, not higher. Trials of 100 mg Aflapin a day for 30 and 180 days also reduced knee pain against placebo (PMID 35512759, 39700461). A 999 mg dose of a non-enriched extract is a different product and is not plotted. The Cochrane authors state that the optimal daily dose is still to be determined.
AI-estimated from published studies. Interpret as directional guidance.
Boswellia has a higher evidence score (7.5/10 vs 7.5/10) and wins in 1 of 3 categories.
For joint health & mobility, Boswellia has a higher relevance score (92 vs 85).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.